JP2016502515A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016502515A5 JP2016502515A5 JP2015540158A JP2015540158A JP2016502515A5 JP 2016502515 A5 JP2016502515 A5 JP 2016502515A5 JP 2015540158 A JP2015540158 A JP 2015540158A JP 2015540158 A JP2015540158 A JP 2015540158A JP 2016502515 A5 JP2016502515 A5 JP 2016502515A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- sequence
- identity
- sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 15
- 102000038129 antigens Human genes 0.000 claims 15
- 108091007172 antigens Proteins 0.000 claims 15
- 102000025417 antigen binding proteins Human genes 0.000 claims 13
- 108091000829 antigen binding proteins Proteins 0.000 claims 13
- 210000004408 Hybridomas Anatomy 0.000 claims 7
- LWGJTAZLEJHCPA-UHFFFAOYSA-N N-(2-chloroethyl)-N-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims 6
- 108090001123 antibodies Proteins 0.000 claims 4
- 102000004965 antibodies Human genes 0.000 claims 4
- 108010045030 monoclonal antibodies Proteins 0.000 claims 4
- 102000005614 monoclonal antibodies Human genes 0.000 claims 4
- 108010047814 Antigen-Antibody Complex Proteins 0.000 claims 3
- 102000003839 Human Proteins Human genes 0.000 claims 2
- 108090000144 Human Proteins Proteins 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12290383 | 2012-11-05 | ||
| EP12290383.4 | 2012-11-05 | ||
| PCT/EP2013/073036 WO2014068139A1 (en) | 2012-11-05 | 2013-11-05 | Novel antigen binding proteins and their use as addressing product for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016502515A JP2016502515A (ja) | 2016-01-28 |
| JP2016502515A5 true JP2016502515A5 (US07794700-20100914-C00152.png) | 2016-12-22 |
| JP6445444B2 JP6445444B2 (ja) | 2018-12-26 |
Family
ID=47278721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540158A Active JP6445444B2 (ja) | 2012-11-05 | 2013-11-05 | 新規抗原結合タンパク質および癌の治療のためのアドレッシング産物（ａｄｄｒｅｓｓｉｎｇｐｒｏｄｕｃｔ）としてのそれらの使用 |
Country Status (14)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016518382A (ja) * | 2013-04-26 | 2016-06-23 | ピエール、ファーブル、メディカマン | Ａｘｌ抗体薬物複合体および癌の治療のためのその使用 |
| KR102586656B1 (ko) | 2014-07-11 | 2023-10-11 | 젠맵 에이/에스 | Ａｘｌ에 결합하는 항체 |
| EP3229836B1 (en) * | 2014-12-09 | 2019-11-13 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Human monoclonal antibodies against axl |
| CN116410318A (zh) * | 2014-12-18 | 2023-07-11 | 卑尔根技术锻造股份公司 | 抗axl拮抗抗体 |
| EP3297663A4 (en) * | 2015-05-18 | 2018-12-19 | Agensys, Inc. | Antibodies that bind to axl proteins |
| JP6857138B2 (ja) | 2015-05-18 | 2021-04-14 | アジェンシス，インコーポレイテッド | Ａｘｌタンパク質に結合する抗体 |
| EP3319993B1 (en) * | 2015-07-10 | 2020-01-15 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
| GB201610902D0 (en) * | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
| CN110483639A (zh) | 2018-05-15 | 2019-11-22 | 复旦大学 | 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途 |
| GB201912059D0 (en) | 2019-08-22 | 2019-10-09 | Bergenbio As | Combaination therapy of a patient subgroup |
| GB202004189D0 (en) | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
| WO2021202592A2 (en) * | 2020-03-30 | 2021-10-07 | Oregon Health & Science University | Monoclonal antibodies for intracellular delivery of payloads |
| IL297132A (en) | 2020-04-08 | 2022-12-01 | Bergenbio Asa | axl inhibitors for antiviral therapy |
| GB202006072D0 (en) | 2020-04-24 | 2020-06-10 | Bergenbio Asa | Method of selecting patients for treatment with cmbination therapy |
| GB202104037D0 (en) | 2021-03-23 | 2021-05-05 | Bergenbio Asa | Combination therapy |
| WO2022212790A1 (en) * | 2021-03-31 | 2022-10-06 | President And Fellows Of Harvard College | Methods of modulating hair growth |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| US5079233A (en) | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| MX2011011825A (es) * | 2009-05-11 | 2011-12-06 | U3 Pharma Gmbh | Anticuerpos humanizados para axl. |
| BRPI1011145A2 (pt) * | 2009-05-15 | 2016-03-15 | Chugai Pharmaceutical Co Ltd | anticorpo anti-axl |
| WO2011014457A1 (en) | 2009-07-27 | 2011-02-03 | Genentech, Inc. | Combination treatments |
| US20110302970A1 (en) | 2010-06-15 | 2011-12-15 | Keybrid, Inc. | Key - Key holder Combination |
| WO2011159980A1 (en) * | 2010-06-18 | 2011-12-22 | Genentech, Inc. | Anti-axl antibodies and methods of use |
| EP2589609A1 (en) * | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
-
2013
- 2013-11-05 TW TW102140130A patent/TWI609887B/zh active
- 2013-11-05 ES ES13789243T patent/ES2871815T3/es active Active
- 2013-11-05 BR BR112015010046-5A patent/BR112015010046B1/pt active IP Right Grant
- 2013-11-05 US US14/440,491 patent/US9624308B2/en active Active
- 2013-11-05 JP JP2015540158A patent/JP6445444B2/ja active Active
- 2013-11-05 DK DK13789243.6T patent/DK2914630T3/da active
- 2013-11-05 KR KR1020157012651A patent/KR102167228B1/ko active IP Right Grant
- 2013-11-05 PL PL13789243T patent/PL2914630T3/pl unknown
- 2013-11-05 CN CN201380067776.9A patent/CN104955842B/zh active Active
- 2013-11-05 EP EP13789243.6A patent/EP2914630B1/en active Active
- 2013-11-05 HU HUE13789243A patent/HUE054115T2/hu unknown
- 2013-11-05 CA CA2890265A patent/CA2890265C/en active Active
- 2013-11-05 AR ARP130104035A patent/AR093357A1/es active IP Right Grant
- 2013-11-05 WO PCT/EP2013/073036 patent/WO2014068139A1/en active Application Filing
